We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$328M
AUM Growth
-$55.1M
Cap. Flow
-$44.7M
Cap. Flow %
-13.62%
Top 10 Hldgs %
42.21%
Holding
136
New
34
Increased
27
Reduced
16
Closed
41

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.8M
2
SLNO
Soleno Therapeutics
SLNO
+$14.3M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.24M
4
TGTX icon
TG Therapeutics
TGTX
+$6.09M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.61M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
ARGX icon
argenx
ARGX
+$3.66M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.54M
4
LLY icon
Eli Lilly
LLY
+$3.49M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 49.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
101
Ascendis Pharma A/S
ASND
$16B
– –
-8,321
Closed -$1.3M
BMEA icon
102
PUT
Biomea Fusion
BMEA
$84.6M
– –
-170,100
Closed -$362K
CADL icon
103
Candel Therapeutics
CADL
$733M
– –
-25,045
Closed -$142K
CAPR icon
104
CALL
Capricor Therapeutics
CAPR
$223M
– –
-30,300
Closed -$288K
CMPX icon
105
CALL
Compass Therapeutics
CMPX
$344M
– –
-200,000
Closed -$380K
CNTA
106
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-164,048
Closed -$2.36M
CORT icon
107
CALL
Corcept Therapeutics
CORT
$12.4B
– –
-40,000
Closed -$4.57M
CYTK icon
108
Cytokinetics
CYTK
$10.5B
– –
-20,000
Closed -$804K
EOLS icon
109
PUT
Evolus
EOLS
$385M
– –
-50,000
Closed -$602K
EWTX icon
110
CALL
Edgewise Therapeutics
EWTX
$4.13B
– –
-98,200
Closed -$2.16M
GOSS icon
111
Gossamer Bio
GOSS
$82.9M
– –
-269,589
Closed -$294K
IMUX icon
112
CALL
Immunic
IMUX
$190M
– –
-31,780
Closed -$346K
JAZZ icon
113
PUT
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-100
Closed -$12.4K
KALV
114
CALL
DELISTED
KalVista Pharmaceuticals
KALV
– –
-103,300
Closed -$1.19M
KALV
115
DELISTED
KalVista Pharmaceuticals
KALV
– –
-135,509
Closed -$1.56M
KROS icon
116
CALL
Keros Therapeutics
KROS
$199M
– –
-147,100
Closed -$1.5M
KROS icon
117
PUT
Keros Therapeutics
KROS
$199M
– –
-65,800
Closed -$671K
MREO
118
Mereo BioPharma
MREO
$54.7M
– –
-492,215
Closed -$1.19M
NVO
119
Novo Nordisk
NVO
$208B
– –
-24,618
Closed -$1.67M
NVO
120
PUT
Novo Nordisk
NVO
$208B
– –
-124,600
Closed -$8.65M
PCVX icon
121
PUT
Vaxcyte
PCVX
$7.81B
– –
-51,600
Closed -$1.95M
QURE icon
122
uniQure
QURE
$3.03B
– –
-36,500
Closed -$491K
REGN icon
123
PUT
Regeneron Pharmaceuticals
REGN
$78.5B
– –
-20,000
Closed -$12.7M
RLAY icon
124
CALL
Relay Therapeutics
RLAY
$4.1B
– –
-131,400
Closed -$344K
RYTM icon
125
Rhythm Pharmaceuticals
RYTM
$6.81B
– –
-50,000
Closed -$2.65M
2 3 4
5
6

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Diadema Partners held 136 positions worth $328M, down 14% from $383M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Diadema Partners withdrew a net $44.7M in Q2 2025, closing 41 positions and reducing 16 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $3.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 33% a quarter earlier.

Against the trend, Diadema Partners opened a new position in Amgen worth $14.5M.

  • Diadema Partners's largest Q2 2025 buy was Amgen: 52,100 shares worth $14.5M.
  • Diadema Partners added most to Soleno Therapeutics in Q2 2025, an estimated $14.3M increase.
  • Diadema Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Alnylam Pharmaceuticals in Q2 2025, selling an estimated $3.54M.
  • Diadema Partners's ten largest holdings make up 42% of its $328M portfolio in Q2 2025.
  • Diadema Partners opened 34 new positions and closed 41 in Q2 2025.
  • Diadema Partners's portfolio value fell 14% quarter-over-quarter to $328M.

Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.